Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 November 2020 | Story Ruan Bruwer | Photo Varsity Sports
Lefébre Rademan, the country’s top student netball player in 2019, has been snatched up by English netball club London Pulse to play in England in 2021.

 

Attempting to become an even better netballer, former Kovsies netball captain Lefébre Rademan decided to jet off to England to play in their league.

Rademan was contracted by London Pulse to compete in the European Superleague in 2021. She will be the fourth Kovsie after Maryka Holtzhausen (2015 and 2018-2019), Karla Pretorius (2016), and Khanyisa Chawane (2020) to play in the league.

Rademan said it was an easy decision, even though it will be far and a long time away from home. The league runs from February to July, with a pre-season in December. She will continue with her master’s degree at the University of the Free State next year.

“I am not going to play netball forever and such an opportunity doesn’t come often. Having competed against England, New Zealand, and Jamaica earlier in the year, I realised they play at a much higher level and if I want to improve and become the best, I would also need to move to a next level.”

“As a goal attack, having Protea teammate Sigi Burger (goal shooter) at the same club, will be an advantage for both of us and for the Proteas as a combination.”

Rademan has had a great past two years, making her Protea debut (12 tests in total) and receiving a number of accolades, such as the Varsity Netball Player of the Tournament in 2019.

In the Telkom Netball League in October, captaining the Free State Crinums, she was named Shooter of the Tournament. She was Player of the Match twice. Her goal average of 88,1% was the highest in the competition.

“Last year was such a good year for me personally, but that remains in the past. You can’t become complacent. I want to keep working hard and become a much better player,” Rademan said.

 

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept